PositoAI/ US/ ImmunityBio, Inc.

ImmunityBio, Inc.

NasdaqGS: IBRX · Healthcare

Positivity Index

#6,510 / 6,774

Global

#3,759 / 4,000

United States

Positivity Score

-22,108

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

ImmunityBio, Inc. — Overview & Financial Snapshot

ImmunityBio, Inc. (NasdaqGS: IBRX) is a Healthcare company, ranked #6,510 of 6,774 companies globally and #3,759 of 4,000 in United States on PositoAI, with a Positivity Score of -22,108. Its market capitalisation is ₹83,132.26 Cr ($8.81B), P/E ratio is -8.6 and P/B ratio is -8.41. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

P/B Ratio -8.41

P/E Ratio -8.6

D/E Ratio -1.04

ROE —

Owes vs Owns ? 2.66× Owes more than it owns $2.66 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-91.56$-0.97

Forward EPS ₹-15.10$-0.16

Beta 0.03

Market Cap ₹83,132.26 Cr$8.81B

What these numbers mean →

What does ImmunityBio, Inc. do?

What is ImmunityBio, Inc.'s P/E and P/B ratio?

ImmunityBio, Inc. has a P/E ratio of -8.6 and a P/B ratio of -8.41.

What is ImmunityBio, Inc.'s debt-to-equity ratio?

ImmunityBio, Inc. has a debt-to-equity ratio of -1.04.

How much does ImmunityBio, Inc. owe compared with what it owns?

ImmunityBio, Inc. owes $2.66 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.

What is ImmunityBio, Inc.'s Positivity rank?

ImmunityBio, Inc. is ranked #6,510 of 6,774 companies globally and #3,759 of 4,000 in United States on PositoAI, with a Positivity Score of -22,108.

Does ImmunityBio, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for ImmunityBio, Inc..

Where can I read the latest news about ImmunityBio, Inc.?

Recent headlines about ImmunityBio, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does ImmunityBio, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of ImmunityBio, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.